Patents by Inventor Martha J. Whitehouse
Martha J. Whitehouse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180221446Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS: 1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.Type: ApplicationFiled: September 8, 2017Publication date: August 9, 2018Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Publication number: 20160120943Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.Type: ApplicationFiled: September 28, 2015Publication date: May 5, 2016Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Patent number: 9149507Abstract: The present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF-9 of SEQ ID NO:13, or an angiogenically active fragment or mutein thereof. The invention is also directed to a method for inducing angiogenesis in the heart of a patient, comprising administering into at least one coronary vessel of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant FGF-9 of SEQ ID NO:13, or an angiogenically active fragment or mutein thereof.Type: GrantFiled: December 6, 2013Date of Patent: October 6, 2015Assignee: Novartis Vaccines and Dignostics, Inc.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Publication number: 20140142038Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.Type: ApplicationFiled: December 6, 2013Publication date: May 22, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Patent number: 8618052Abstract: The present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-5 of SEQ ID NO:9, or an angiogenically active fragment or mutein thereof. The invention is also directed to a method for inducing angiogenesis in the heart of a patient, comprising administering into at least one coronary vessel of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant FGF-5 of SEQ ID NO:9, or an angiogenically active fragment or mutein thereof.Type: GrantFiled: November 17, 2010Date of Patent: December 31, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Patent number: 8415301Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: GrantFiled: May 15, 2009Date of Patent: April 9, 2013Assignee: Corthera, Inc.Inventors: Elaine Unemori, Sam L Teichman, Gad Cotter, Dennis R Stewart, Martha J Whitehouse
-
Patent number: 8372809Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: GrantFiled: September 23, 2011Date of Patent: February 12, 2013Assignee: Corthera, Inc.Inventors: Elaine Unemori, Sam L Teichman, Gad Cotter, Dennis R Stewart, Martha J Whitehouse
-
Publication number: 20120165245Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.Type: ApplicationFiled: November 17, 2010Publication date: June 28, 2012Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Publication number: 20120040903Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: ApplicationFiled: May 15, 2009Publication date: February 16, 2012Inventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis R. Stewart, Martha J. Whitehouse
-
Publication number: 20110144019Abstract: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.Type: ApplicationFiled: May 15, 2009Publication date: June 16, 2011Inventors: Elaine Unemori, Sam L. Teichman, Thomas Dschietzig, Dennis R. Stewart, Martha J. Whitehouse
-
Patent number: 7858584Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 ?g/kg to 36 ?g/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof.Type: GrantFiled: February 24, 2009Date of Patent: December 28, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Publication number: 20090170776Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 ?g/kg to 36 ?g/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof.Type: ApplicationFiled: February 24, 2009Publication date: July 2, 2009Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Patent number: 7511019Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 ?g/kg to 36 ?g/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof.Type: GrantFiled: September 29, 2005Date of Patent: March 31, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Patent number: 7112560Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety.Type: GrantFiled: June 4, 2004Date of Patent: September 26, 2006Assignee: Chiron CorporationInventor: Martha J. Whitehouse
-
Publication number: 20030191093Abstract: Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase component.Type: ApplicationFiled: December 3, 2002Publication date: October 9, 2003Applicant: Novacea, Inc.Inventors: Andrew X. Chen, Jun Fan, Xi-Yun Yu, Martha J. Whitehouse
-
Publication number: 20020165160Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 &mgr;g/kg to 36 &mgr;g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 &mgr;g/kg to 36 &mgr;g/kg of an FGF of any one of SEQ ID NOS: 1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof.Type: ApplicationFiled: April 25, 2002Publication date: November 7, 2002Applicant: Chiron CorporationInventor: Martha J. Whitehouse
-
Patent number: 6451303Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 &mgr;g/kg to 36 &mgr;g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 &mgr;g/kg to 36 &mgr;g/kg of an FGF of any one of SEQ ID NOS: 1-3, 5, 8-10 or 12-14 or an angiogenically active fragment or mutein thereof.Type: GrantFiled: October 13, 1999Date of Patent: September 17, 2002Assignee: Chiron CorporationInventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Publication number: 20020072489Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 &mgr;g/kg to 48 &mgr;g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety.Type: ApplicationFiled: January 26, 2001Publication date: June 13, 2002Inventor: Martha J. Whitehouse